Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P030031/S142

THERMOCOOL SMARTTOUCH SF Catheter

Biosense Webster, Inc. · Decision date Sep 2, 2026

MEDTECHLEDGER EXPLANATIONP030031/S142

What did the FDA approve?

This supplement to PMA P030031 records a labeling change for the THERMOCOOL SMARTTOUCH SF catheter. The FDA database lists the supplement type as "Normal 180 Day Track" and the reason as "Labeling Change - Indications/instructions/shelf life/tradename." The exact labeling element that changed is not specified in the supplied fields, so the specific revised indication, instruction, shelf life, or trade name cannot be identified from this record alone.

The statement describes the catheter's approved indications: mapping, Type I atrial flutter in patients 18 or older, recurrent symptomatic paroxysmal atrial fibrillation under certain conditions, and drug refractory recurrent symptomatic persistent atrial fibrillation when used with compatible three-dimensional electroanatomic mapping systems. It also states the device provides real-time contact force measurement and location information with the CARTO 3 System. These descriptions are the source statement's reported purpose and are not independent proof of safety or effectiveness.

FDA approval order statement

The Biosense Webster THERMOCOOL SMARTTOUCH SF Uni-/Bi-DirectionalNavigation Catheter and related accessory devices are indicated for catheter-based cardiac electrophysiological mapping (stimulating and recording) and, when used with a compatible RF generator, for the treatment of: Type I atrial flutter in patients age 18 or older. Recurrent symptomatic paroxysmal atrial fibrillation, when used with compatible three-dimensional electroanatomic mapping systems, as an alternative to antiarrhythmic drug therapy, or as an initial rhythm control strategy. Drug refractory recurrent symptomatic persistent atrial fibrillation (defined as continuous atrial fibrillation that is sustained beyond 7 days but less than 1 year), refractory or intolerant to at least one Class I or III antiarrhythmic medicine, when used with compatible three-dimensional electroanatomic mapping systems.The Biosense Webster THERMOCOOL SMARTTOUCH SF Uni-/Bi-DirectionalNavigation Catheter provides a real-time measurement of contact force between the catheter tip and the heart wall, as well as location information when used with the CARTO 3 System.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Cardiovascular
Decision date
Sep 2, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P030031/S142
Regulatory pathway
PMA supplement
Product code
OAD
Decision code
APPR
Decision date
Sep 2, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: catheter, percutaneous, cardiac ablation, for treatment of atrial flutter.

Product code
OAD
FDA device class
3

For the original device and its historical approval scope, see PMA P030031. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P030031 · Original PMA

    BIOSENSE WEBSTER NAVISTAR/CELSIUS THERMO COOL DIAGNOSTIC/ABLATION DEFLECTABLE TIP CATHETERS

  2. P030031/S142 received

    Application receipt date recorded by FDA.

  3. P030031/S142 · FDA decision

    Normal 180 Day Track

  4. P030031/S146 · Related supplement

    EZ STEER THERMOCOOL NAV BI-DIRECTIONAL ELECTROPHYSIOLOGY CATHETER; THERMOCOOL SMARTTOUCH BI-DIRECTIONAL NAVIGATION CATHE

Timeline entries are records held by MedtechLedger for P030031. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P030031

Explore the linked device profile

Other records with product code OAD

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biosense Webster, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
31 Technology Dr., Suite 200, Irvine, CA, 92618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records